In its September issue, Inc. Magazine revealed that ProSomnus Sleep Technologies is ranked at 3,036 on its annual Inc. 5000 list, the most prestigious ranking of the nation's fastest-growing private companies. This is the third year in a row that ProSomnus has earned this honor. The list represents a unique look at the most successful companies within the American economy's most dynamic segment, its independent small businesses. Intuit, Zappos, Under Armour, Microsoft, Patagonia, and many other well-known names gained their first national exposure as honorees on the Inc. 5000.

"It is an honor to be named to the Inc. 5000 for the third consecutive year," says Len Liptak, CEO of ProSomnus, which has its headquarters at Hacienda. "Consistent performance does not happen by accident. I am very proud that Team ProSomnus is committed to continuous improvement and sustained excellence, and grateful that dental sleep medicine providers trust ProSomnus devices when treating their patients for sleep apnea."

ProSomnus devices are rapidly emerging as the leading alternative to continuous positive airway pressure (CPAP) therapy for the treatment of Obstructive Sleep Apnea (OSA). Effective, non-intrusive and easy to use, each ProSomnus device is prescribed by a physician and fitted by a dental sleep medicine specialist. ProSomnus devices are an excellent option for people with OSA who prefer a more comfortable treatment experience.

"There's no surprise ProSomnus was named to Inc. 5000 three years in a row," according to Edward T. Sall, MD, DDS, MBA, Medical Director for ProSomnus Sleep Technologies. "ProSomnus continues to innovate as a leading medical device manufacturer providing preferred patient treatment options for Obstructive Sleep Apnea. The introduction of the ProSomnus EVO Sleep Device is a result of listening to clinicians and providing an appliance that is unsurpassed in comfort, ease of insertion, and efficacy. Sleep physicians should now feel confident in the increased role of oral appliance therapy as a primary treatment for their patients with mild to moderate OSA and for severe patients who fail or abandon CPAP."

OSA is a chronic sleep breathing disorder that affects one billion people worldwide. It is associated with severe comorbidities including heart disease and stroke, significantly higher healthcare costs, and an increase in everyday issues such as traffic accidents, workplace errors, and educational performance. Symptoms of OSA include snoring, daytime sleepiness, morning headaches, and pauses in breathing during sleep.

"The 2021 Inc. 5000 list feels like one of the most important rosters of companies ever compiled," says Scott Omelianuk, Editor-in-Chief of Inc. "Building one of the fastest-growing companies in America in any year is a remarkable achievement. Building one in the crisis we've lived through is just plain amazing. This kind of accomplishment comes with hard work, smart pivots, great leadership, and the help of a whole lot of people."

For more information about ProSomnus Sleep Technologies, please visit prosomnus.com.